Poorly differentiated and anaplastic thyroid cancer

Cancer Control

Volumn 13, Issue 2, 2006, Pages 119-128

  Patel, Kepal N ^a   Shaha, Ashok R ^b  

^a STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; RADIOACTIVE IODINE;

ANAPLASTIC CARCINOMA; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CLINICAL FEATURE; COMPARATIVE STUDY; DISEASE COURSE; EXTERNAL BEAM RADIOTHERAPY; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MEDICAL LITERATURE; PALLIATIVE THERAPY; PATHOLOGY; PROGNOSIS; REVIEW; THYROID CANCER; THYROID CARCINOMA; THYROIDECTOMY;

EID: 33745199172     PISSN: 10732748     EISSN: 15262359     Source Type: Journal    
DOI: 10.1177/107327480601300206     Document Type: Review

References (105)

1. Shaha AR. Implications of prognostic factors and risk groups in the management of differentiated thyroid cancer. Laryngoscope. 2004;114:393-402.
2. Sakamoto A., Kasai n, Sugano H. Poorly differentiated carcinoma of the thyroid. A clinicopathologic entity for a high-risk group of papillary and follicular carcinomas. Cancer. 1983;52:1849-1855.
3. Carcangiu ML, Zampi G, Rosai J, et al. Poorly differentiated ("insular") thyroid carcinoma: a reinterpretation of Langhans' "wuchernde Struma." Am J Surg Pathol. 1984;8:655-668.
4. Nishida T, Katayama S, Tsujimoto M, et al. Clinicopathological significance of poorly differentiated thyroid carcinoma. Am J Surg Pathol. 1999;23:205-211.
5. Sobrinho-Simoes M, Sambade C, Fonseca E, et al. Poorly differentiated carcinomas of the thyroid gland: a review of the clinicopathologic features of a series of 28 cases of a heterogeneous, clinically aggressive group of thyroid tumors. Int J Surg Pathol. 2002;10:123-131.
6. Carcangiu ML, Bianchi S. Diffuse sclerosing variant of papillary thyroid carcinoma: clinicopathologic study of 15 cases. Am J Surg Pathol. 1989;13:1041-1049.
7. Pilotti S, Collini P, Manzari A, et al. Poorly differentiated forms of papillary thyroid carcinoma: distinctive entities or morphological patterns? Semin Diagn Pathol. 1995;12:249-255.
8. Sobrinho-Simoes M, Nesland JM, Johannessen JV. Columnar-cell carcinoma. Another variant of poorly differentiated carcinoma of the thyroid. Am J Clin Pathol. 1988;89:264-267.
9. Akslen LA, LiVolsi VA. Poorly differentiated thyroid carcinoma: it is important. Am J Surg Pathol. 2000;24:310-313.
10. Nikiforov YE, Erickson LA, Nikiforova MN, et al. Solid variant of papillary thyroid carcinoma: incidence, clinical-pathologic characteristics, molecular analysis, and biologic behavior. Am J Surg Pathol. 2001;25:1478-1484.
11. Nikiforov Y, Gnepp DR. Pediatric thyroid cancer after the Chernobyl disaster: pathomorphologic study of 84 cases (1991-1992) from the Republic of Belarus. Cancer. 1994;74:748-666.
12. Nikiforov Y, Gnepp DR, Fagin JA. Thyroid lesions in children and adolescents after the Chernobyl disaster: implications for the study of radiation tumorigenesis. J Clin Endocrinol Metab. 1996;81:9-14.
13. Yunta PJ, Ponce JL, Prieto M, et al. The importance of a tumor capsule in columnar cell thyroid carcinoma: a report of two cases and review of the literature. Thyroid. 1999;9:815-819.
14. Burman KD, Ringel MD, Wartofsky L, et al. Unusual types of thyroid neoplasms. Endocrinol Metab Clin North Am. 1996;25:49-68.
15. Livolsi VA. Surgical Pathology of the Thyroid. Philadelphia, Pa: Saunders; 1990.
16. Langhans T. Uber die epithelialen formen der malignen struma. Virchows Arch A Pathol Anat. 1907;189:69-188.
17. Hedinger CE. Thyroid Cancer. Berlin, New York: Springer; 1969.
18. Meissner WA, Warren S. Tumors of the Thyroid Gland. Washington, DC: Armed Forces Institute of Pathology; 1969.
19. Woolner LB, Beahrs OH, Black BM, et al. Classification and prognosis of thyroid carcinoma. A study of 885 cases observed in a thirty year period. Am J Surg. 1961;102:354-387.
20. Albareda M, Puig-Domingo M, Wengrowicz S, et al. Clinical forms of presentation and evolution of diffuse sclerosing variant of papillary carcinoma and insular variant of follicular carcinoma of the thyroid. Thyroid. 1998;8:385-391.
21. Papotti M, Botto Micca F, Favero A, et al. Poorly differentiated thyroid carcinomas with primordial cell component: a group of aggressive lesions sharing insular, trabecular, and solid patterns. Am J Surg Pathol. 1993;17:291-301.
22. Pilotti S, Collini P, Mariani L, et al. Insular carcinoma: a distinct de novo entity among follicular carcinomas of the thyroid gland. Am J Surg Pathol. 1997;21:1466-1473.
23. Hwang TS, Suh JS, Kim YI, et al. Poorly differentiated carcinoma of the thyroid retrospective clinical and morphologic evaluation. J Korean Med Sci. 1990;5:47-52.
24. Flynn SD, Forman BH, Stewart AF, et al. Poorly differentiated ("insular") carcinoma of the thyroid gland: an aggressive subset of differentiated thyroid neoplasms. Surgery. 1988;104:963-970.
25. Lam KY, Lo CY, Chan KW, et al. Insular and anaplastic carcinoma of the thyroid: a 45-year comparative study at a single institution and a review of the significance of p53 and p21. Ann Surg. 2000;231:329-338.
26. Machens A, Hinze R, Lautenschlager C, et al. Multivariate analysis of clinicopathologic parameters for the insular subtype of differentiated thyroid carcinoma. Arch Surg. 2001;136:941-944.
27. Takeuchi Y, Daa T, Kashima K, et al. Mutations of p53 in thyroid carcinoma with an insular component. Thyroid. 1999;9:377-381.
28. Killeen RM, Barnes L, Watson CG, et al. Poorly differentiated ('insular') thyroid carcinoma: report of two cases and review of the literature. Arch Otolaryngol Head Neck Surg. 1990;116:1082-1086.
29. van den Brekel MW, Hekkenberg RJ, Asa SL, et al. Prognostic features in tall cell papillary carcinoma and insular thyroid carcinoma. Laryngoscope. 1997;107:254-259.
30. Rodriguez JM, Parrilla P, Moreno A, et al. Insular carcinoma: an infrequent subtype of thyroid cancer. J Am Coll Surg. 1998;187:503-508.
31. Ashfaq R, Vuitch F, Delgado R, et al. Papillary and follicular thyroid carcinomas with an insular component. Cancer. 1994;73:416-423.
32. Sasaki A, Daa T, Kashima K, et al. Insular component as a risk factor of thyroid carcinoma. Pathol Int. 1996;46:939-946.
33. Pietribiasi F, Sapino A, Papotti M, et al. Cytologic features of poorly differentiated "insular" carcinoma of the thyroid, as revealed by fine-needle aspiration biopsy. Am J Clin Pathol. 1990;94:687-692.
34. Pilotti S, Collini P, Del Bo R, et al. A novel panel of antibodies that segregates immunocytochemically poorly differentiated carcinoma from undifferentiated carcinoma of the thyroid gland. Am J Surg Pathol. 1994;18:1054-1064.
35. Sywak M, Pasieka JL, Ogilvie T, et al. A review of thyroid cancer with intermediate differentiation. J Surg Oncol. 2004;86:44-54.
36. Wreesmann VB, Ghossein RA, Patel SG, et al. Genome-wide appraisal of thyroid cancer progression. Am J Pathol. 2002;161:1549-1556.
37. Decaussin M, Bernard MH, Adeleine P, et al.Thyroid carcinomas with distant metastases: a review of 111 cases with emphasis on the prognostic significance of an insular component. Am J Surg Pathol. 2002;26:1007-1015.
38. Justin EP, Seabold JE, Robinson RA, et al. Insular carcinoma: a distinct thyroid carcinoma with associated iodine-131 localization. J Nucl Med. 1991;32:1358-1363.
39. Brierley JD, Tsang RW. External-beam radiation therapy in the treatment of differentiated thyroid cancer. Semin Surg Oncol. 1999;16:42-49.
40. Asakawa H, Kobayashi T, Komoike Y, et al. Chemosensitivity of anaplastic thyroid carcinoma and poorly differentiated thyroid carcinoma. Anticancer Res. 1997;17:2757-2762.
41. Wang W, Macapinlac H, Larson SM, et al. [18F]-2-fluoro-2-deoxy-Dglucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab. 1999;84:2291-2302.
42. Wang W, Larson SM, Fazzari M, et al. Prognostic value of [18F] fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab. 2000;85:1107-1113.
43. Gilliland FD, Hunt WC, Morris DM, et al. Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973-1991. Cancer. 1997;79:564-573.
44. Nel CJ, van Heerden JA, Goellner JR, et al.. Anaplastic carcinoma of the thyroid: a clinicopathologic study of 82 cases. Mayo Clin Proc. 1985;60:51-58.
45. Venkatesh YS, Ordonez NG, Schultz PN, et al. Anaplastic carcinoma of the thyroid: a clinicopathologic study of 121 cases. Cancer. 1990;66:321-330.
46. Lo CY, Lam KY, Wan KY, et al. Anaplastic carcinoma of the thyroid. Am J Surg. 1999;177:337-339.
47. Tan RK, Finley RK III, Driscoll D, et al. Anaplastic carcinoma of the thyroid: a 24-year experience. Head Neck. 1995;17:41-48.
48. Schaefer CJ. Long-term survival in anaplastic thyroid cancer. Md Med J. 1988;37:873-874.
49. Pasieka JL. Anaplastic thyroid cancer. Curr Opin Oncol. 2003;15:78-83.
50. Holting T, Moller P, Tschahargane C, et al. Immunohistochemical reclassification of anaplastic carcinoma reveals small and giant cell lymphoma. World J Surg. 1990;14:291-295.
51. Tobler A, Maurer R, Hedinger CE, et al. Undifferentiated thyroid tumors of diffuse small cell type. Histological and immunohistochemical evidence for their lymphomatous nature. Virchows Arch A Pathol Anat Histopathol. 1984;404:117-126.
52. Myskow MW, Krajewski AS, Dewar AE, et al. The role of immunoperoxidase techniques on paraffin embedded tissue in determining the histogenesis of undifferentiated thyroid neoplasms. Clin Endocrinol (Oxf). 1986;24:335-341.
53. Bakiri F, Djemli FK, Mokrane LA, et al. The relative roles of endemic goiter and socioeconomic development status in the prognosis of thyroid carcinoma. Cancer. 1998;82:1146-1153.
54. Pettersson B, Coleman MP, Ron E, et al. Iodine supplementation in Sweden and regional trends in thyroid cancer incidence by histopathologic type. Int J Cancer. 1996;65:13-19.
55. McIver B, Hay ID, Giuffrida DF, et al. Anaplastic thyroid carcinoma: a 50-year experience at a single institution. Surgery. 2001;130:1028-1034.
56. Demeter JG, De Jong SA, Lawrence AM, et al. Anaplastic thyroid carcinoma: risk factors and outcome. Surgery. 1991;110:956-963.
57. Ain KB. Anaplastic thyroid carcinoma: a therapeutic challenge. Semin Surg Oncol. 1999;16:64-69.
58. Fagin JA. Molecular genetics of human thyroid neoplasms. Annu Rev Med. 1994;45:45-52.
59. Carcangiu ML, Steeper T, Zampi G, et al. Anaplastic thyroid carcinoma: a study of 70 cases. Am J Clin Pathol. 1985;83:135-158.
60. Nishiyama RH, Dunn EL, Thompson NW. Anaplastic spindle-cell and giant-cell tumors of the thyroid gland. Cancer. 1972;30:113-127.
61. Ibanez ML, Russell WO, Albores-Saavedra J, et al. Thyroid carcinoma: biologic behavior and mortality. Postmortem findings in 42 cases, including 27 in which the disease was fatal. Cancer. 1966;19:1039-1052.
62. Moreno Egea A, Rodriguez Gonzalez JM, Sola Perez J, et al. Prognostic value of the tall cell variety of papillary cancer of the thyroid. Eur J Surg Oncol. 1993;19:517-521.
63. Cohen Y, Xing M, Mambo E, et al. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst. 2003;95:625-627.
64. Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer. 2005;12:245-262.
65. Xing M, Westra WH, Tufano RP, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab. 2005;90:6373-6379. Epub 2005 Sep 20.
66. Xing M, Vasko V, Tallini G, et al. BRAF T1796A transversion mutation in various thyroid neoplasms. J Clin Endocrinol Metab. 2004;89:1365-1368.
67. Xu X, Quiros RM, Gattuso P, et al. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res. 2003;63:4561-4567.
68. Puxeddu E, Moretti S, Elisei R, et al. BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. J Clin Endocrinol Metab. 2004;89:2414-2420.
69. Quiros RM, Ding HG, Gattuso P, et al. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations. Cancer. 2005;103:2261-2268.
70. Knauf JA, Ma X, Smith EP, et al. Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res. 2005;65:4238-4245.
71. Pasieka JL. Anaplastic cancer, lymphoma, and metastases of the thyroid gland. Surg Oncol Clin N Am. 1998;7:707-720.
72. Kobayashi T, Asakawa H, Umeshita K, et al. Treatment of 37 patients with anaplastic carcinoma of the thyroid. Head Neck. 1996;18:36-41.
73. Pacheco-Ojeda LA, Martinez AL, Alvarez M, et al. Anaplastic thyroid carcinoma in Ecuador: analysis of prognostic factors. Int Surg. 2001;86:117-121.
74. Us-Krasovec M, Golouh R, Auersperg M, et al. Anaplastic thyroid carcinoma in fine needle aspirates. Acta Cytol. 1996;40:953-958.
75. Wolf BC, Sheahan K, DeCoste D, et al. Immunohistochemical analysis of small cell tumors of the thyroid gland: an Eastern Cooperative Oncology Group study. Hum Pathol. 1992;23:1252-1261.
76. Poppe K, Lahoutte T, Everaert H, et al. The utility of multimodality imaging in anaplastic thyroid carcinoma. Thyroid. 2004;14:981-982.
77. Ain KB. Anaplastic thyroid carcinoma: behavior, biology, and therapeutic approaches. Thyroid. 1998;8:715-726.
78. Tennvall J, Lundell G, Hallquist A, et al. Combined doxorubicin, hyperfractionated radiotherapy, and surgery in anaplastic thyroid carcinoma: report on two protocols. The Swedish Anaplastic Thyroid Cancer Group. Cancer. 1994;74:1348-1354.
79. Hadar T, Mor C, Shvero J, et al. Anaplastic carcinoma of the thyroid. Eur J Surg Oncol. 1993;19:511-516.
80. Giuffrida D, Gharib H. Anaplastic thyroid carcinoma: current diagnosis and treatment. Ann Oncol. 2000;11:1083-1089.
81. Haigh PI, Ituarte PH, Wu HS, et al. Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival. Cancer. 2001;91:2335-2342.
82. Nilsson O, Lindeberg J, Zedenius J, et al. Anaplastic giant cell carcinoma of the thyroid gland: treatment and survival over a 25-year period. World J Surg. 1998;22:725-730.
83. Junor EJ, Paul J, Reed NS, et al. Anaplastic thyroid carcinoma: 91 patients treated by surgery and radiotherapy. Eur J Surg Oncol. 1992;18:83-88.
84. De Crevoisier R, Baudin E, Bachelot A, et al. Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy. Int J Radiat Oncol Biol Phys. 2004;60:1137-1143.
85. Thyroid Carcinoma Task Force. AACE/AAES medical/surgical guidelines for clinical practice: management of thyroid carcinoma. American Association of Clinical Endocrinologists. American College of Endocrinology. Endocr Pract. 2001;7:202-220.
86. Pellitteri PK, McCaffrey TV. Endocrine Surgery of the Head and Neck. Clifton Park, NY: Thomson Delmar Learning; 2003.
87. Levendag PC, De Porre PM, van Putten WL. Anaplastic carcinoma of the thyroid gland treated by radiation therapy. Int J Radiat Oncol Biol Phys. 1993;26:125-128.
88. Simpson WJ. Anaplastic thyroid carcinoma: a new approach. Can J Surg. 1980;23:25-27.
89. Kim JH, Leeper RD. Treatment of anaplastic giant and spindle cell carcinoma of the thyroid gland with combination Adriamycin and radiation therapy: a new approach. Cancer. 1983;52:954-957.
90. Kim JH, Leeper RD. Treatment of locally advanced thyroid carcinoma with combination doxorubicin and radiation therapy. Cancer. 1987;60:2372-2375.
91. Tennvall J, Lundell G, Wahlberg P, et al. Anaplastic thyroid carcinoma: three protocols combining doxorubicin, hyperfractionated radiotherapy and surgery. Br J Cancer. 2002;86:1848-1853.
92. Wong CS, Van Dyk J, Simpson WJ. Myelopathy following hyperfractionated accelerated radiotherapy for anaplastic thyroid carcinoma. Radiother Oncol. 1991;20:3-9.
93. Shimaoka K, Schoenfeld DA, DeWys WD, et al. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer. 1985;56:2155-2160.
94. Ahuja S, Ernst H. Chemotherapy of thyroid carcinoma. J Endocrinol Invest. 1987;10:303-310.
95. De Besi P, Busnardo B, Toso S, et al. Combined chemotherapy with bleomycin, adriamycin, and platinum in advanced thyroid cancer. J Endocrinol Invest. 1991;14:475-480.
96. Williams SD, Birch R, Einhorn LH. Phase II evaluation of doxorubicin plus cisplatin in advanced thyroid cancer: a Southeastern Cancer Study Group Trial. Cancer Treat Rep. 1986;70:405-407.
97. Ain KB, Egorin MJ, DeSimone PA, et al. Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group. Thyroid. 2000;10:587-594.
98. Yeung SC, Xu G, Pan J, et al. Manumycin enhances the cytotoxic effect of paclitaxel on anaplastic thyroid carcinoma cells. Cancer Res. 2000;60:650-656.
99. Xu G, Pan J, Martin C, et al. Angiogenesis inhibition in the in vivo antineoplastic effect of manumycin and paclitaxel against anaplastic thyroid carcinoma. J Clin Endocrinol Metab. 2001;86:1769-1777.
100. Sugino K, Ito K, Mimura T, et al. The important role of operations in the management of anaplastic thyroid carcinoma. Surgery. 2002;131:245-248.
101. Besic N, Auersperg M, Us-Krasovec M, et al. Effect of primary treatment on survival in anaplastic thyroid carcinoma. Eur J Surg Oncol. 2001;27:260-264.
102. Blagosklonny MV, Giannakakou P, Wojtowicz M, et al. Effects of p53-expressing adenovirus on the chemosensitivity and differentiation of anaplastic thyroid cancer cells. J Clin Endocrinol Metab. 1998;83:2516-2522.
103. Nagayama Y, Yokoi H, Takeda K, et al. Adenovirus-mediated tumor suppressor p53 gene therapy for anaplastic thyroid carcinoma in vitro and in vivo. J Clin Endocrinol Metab. 2000;85:4081-4086.
104. Franzen A, Heldin NE. BMP-7-induced cell cycle arrest of anaplastic thyroid carcinoma cells via p21(CIP1) and p27(KIP1). Biochem Biophys Res Commun. 2001;285:773-781.
105. Kotchetkov R, Cinatl J, Krivtchik AA, et al. Selective activity of BSRNase against anaplastic thyroid cancer. Anticancer Res. 2001;21:1035-1042.